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initial clinical evaluation improves the cost-effectiveness of
diagnostic testing for syncope.
Perspective: The most common cause of syncope in patients
of all age groups is vasovagal syncope, which often can be
reliably diagnosed based only on the description of circum-
stances, prodromal symptoms, and residual symptoms.
Other than the history, the most helpful diagnostic test for
vasovagal syncope is head-up tilt. Unfortunately, in this
study, the diagnostic value of neither was evaluated.  
Summary written by: Fred Morady, MD
Systematic Review: Comparative Effectiveness of
Radiofrequency Catheter Ablation for Atrial
Fibrillation
Terasawa T, Balk EM, Chung M, et al.
Ann Intern Med 2009;151:191–202.
Study Design: How effective is radiofrequency catheter abla-
tion (RFCA) of atrial fibrillation (AF)? 
Methods: This was a review of 67 cohort studies, 32 random-
ized controlled trials, and 9 nonrandomized comparative
studies published in 2000-2008 describing results of RFCA of
AF with an 8-mm-tip or irrigated-tip ablation catheter, with
at least 6 months of follow-up.
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Arrhythmias
Yield of Diagnostic Tests in Evaluating Syncopal
Episodes in Older Patients
Mendu ML, McAvay G, Lampert R, Stoehr J, Tinetti ME.
Arch Intern Med 2009;169:1299–1305.
Study Design: How useful are diagnostic tests for syncope in
patients over the age of 65 years?
Methods: The subjects of this retrospective review were 2,106
patients (mean age 79 years) who underwent inpatient eval-
uation for syncope.
Results: The most common etiologies for syncope were:
unknown, 47%; vasovagal, 22%; orthostatic hypotension,
13%; and arrhythmia, 12%. The most commonly performed
diagnostic tests were: electrocardiogram, 99%; telemetry,
95%; cardiac enzymes, 95%; head computed tomography
(CT), 63%; echocardiogram, 39%; and postural blood pres-
sure (BP) recording, 38%. Postural BPs had the highest
diagnostic yield (18-26%); other tests, 0.5-5%. The cost per
cardiac test affecting the diagnosis was significantly lower
when testing was limited to high-risk patients with heart
failure, hematocrit <30%, an abnormal electrocardiogram,
dyspnea, or a systolic BP <90 mm Hg.
Conclusions: Many elderly patients with syncope undergo
unnecessary testing. Testing that is based on the history and
cessfully treated, 3 had coronary sinus perforation or dissec-
tion, whereas in 13 patients, the device was recaptured due
to slippage of the distal anchor (n = 3) and coronary artery
compromise or insufficient reduction in MR (n = 10). One
patient died during follow-up and there were three myocar-
dial infarctions in the periprocedural phase. The major
adverse event rate was 13% at 30 days. At 6 months, the
severity of MR reduction on quantitative echocardiographic
measures ranged from 22% to 32%. There was significant
improvement in the 6-minute walk distance.
Conclusions: The study demonstrates safety, efficacy, and fea-
sibility of percutaneous mitral annuloplasty.
Perspective: This is a rapidly evolving field, and further refine-
ment in the device and better preprocedural imaging will
further improve safety and reduce unsuccessful procedures.
Larger controlled studies will be warranted to confirm clinical
improvement and assess long-term implications of percuta-
neous mitral annuloplasty before it can be used in routine
clinical practice. 
Summary written by: Hitinder S. Gurm, MD 
Congenital Heart Disease
Twenty-Five-Year Outcome of Pediatric Coronary
Artery Bypass Surgery for Kawasaki Disease
Kitamura S, Tsuda E, Kobayashi J.
Circulation 2009;120:60–68. 
Study Question: What is the long-term outcome of pediatric
coronary artery bypass for patients with severe inflammatory
coronary sequelae due to Kawasaki disease?
Methods: A retrospective review was performed at a single
referral center. Indications for surgery included angiographi-
cally significant coronary lesions with stenosis of ≥75%,
presence of clinical signs of myocardial ischemia, or positive
signs of ischemia by exercise or pharmacological stress. Prior
myocardial infarction was also considered an indication for
surgical intervention. 
Results: A total of 114 patients (median age 10, range 1-19
years) underwent surgery and were followed for a median of
19 years. The mean number of distal anastomoses was 1.7 ±
0.8 per patient, with the vast majority (111) involving the
internal thoracic artery, with 24 patients receiving saphe-
nous vein grafts. Both 20- and 25-year survival rates were
95%. There were five deaths, all sudden, except for a late
Results: RFCA as second-line therapy was 3.46 times more
likely to maintain sinus rhythm compared to drug therapy.
One randomized study reported that RFCA as first-line
therapy resulted in freedom from AF over 12 months more
often than drug therapy (88% vs. 37%). A low strength of
evidence suggests that there is not a significant difference
between RFCA and drug therapy in improvement in ejec-
tion fraction or left atrial size, or in the stroke rate at 12
months. Evidence also suggests that RFCA improves qual-
ity of life, promotes avoidance of anticoagulation, and
decreases rehospitalizations to a greater degree than drug
therapy.
Conclusions: RFCA is more effective than medical therapy for
preventing recurrences of AF.
Perspective: Most studies on RFCA of AF are cohort studies
of relatively low scientific quality. At least two large-scale
randomized clinical trials of RFCA versus drug therapy are
currently in progress. However, the optimal ablation strategy
(particularly for persistent AF) is as yet unclear, and ablation
tools continue to evolve, making catheter ablation of AF a
‘moving target.’ 
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Percutaneous Mitral Annuloplasty for Functional
Mitral Regurgitation: Results of the CARILLON
Mitral Annuloplasty Device European Union Study
Schofer J, Siminiak T, Haude M, et al.
Circulation 2009;120:326–333.
Study Design: What is the feasibility and outcome of percuta-
neous mitral annuloplasty?
Methods: This was a single-arm evaluation of percutaneous
mitral annuloplasty performed via the coronary sinus with
the CARILLON Mitral Contour System. Patients with
dilated cardiomyopathy, moderate to severe functional
mitral regurgitation (MR), an ejection fraction <40%, and a
6-minute walk distance between 150 and 450 m were
enrolled in the study. Outcome measures were echocardio-
graphic MR grade, exercise tolerance, New York Heart
Association class, and quality of life, and they were assessed
at baseline and 1 and 6 months.
Results: The study enrolled 48 patients, of whom 18 did not
receive the device. Of the 18 patients who did not get suc-
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CYP2C19*2 variant, and was associated with diminished
clopidogrel response, accounting for 12% of the variation in
platelet aggregation to ADP. The relation between
CYP2C19*2 genotype and platelet aggregation was repli-
cated in clopidogrel-treated patients undergoing coronary
intervention (p = 0.02). Patients with the CYP2C19*2 vari-
ant were more likely (20.9% vs. 10.0%) to have a
cardiovascular ischemic event or death during 1 year of fol-
low-up.
Conclusions: CYP2C19*2 genotype was associated with dimin-
ished platelet response to clopidogrel treatment and poorer
cardiovascular outcomes.
Perspective: This study extends previous work that polymor-
phisms in these enzymes, leading to reduced enzyme
activity, blunt the platelet and clinical response to clopido-
grel. SNP genotyping may be useful in determining
appropriate pharmacotherapy for patients with acute coro-
nary syndromes and those following stenting. The
appropriate alternative treatment (higher clopidogrel dose or
another thienopyridine) for patients testing positive will
need to be determined in future studies. Alternatively, use of
drugs that do not require bioconversion, as standard initial
treatment, could eliminate the need for genotyping.  
Summary written by: Daniel T. Eitzman, MD     
Assessment of Aspirin Resistance Varies on a
Temporal Basis in Patients With Ischaemic Heart
Disease
Muir AR, McMullin MF, Patterson C, McKeown PP.
Heart 2009;95:1225–1229.
Study Question: What is the prevalence of aspirin resistance in
patients with ischemic heart disease, and what is the concor-
dance and repeatability of tests to detect aspirin resistance?
Methods: The authors enrolled 172 patients and measured
platelet function at baseline, 1 week, and 2 weeks later.
Aspirin-induced platelet inhibition was assessed using opti-
cal platelet aggregometry (OPA), platelet function analyser
(PFA-100), and serum and urinary thromboxane B2 (TXB2)
metabolite levels. 
Results: One week after starting aspirin, 1.7% of patients
were aspirin resistant by OPA and 22.1% by PFA-100. At
2 weeks, 4.7% were aspirin resistant by OPA, and 20.3% by
PFA-100. There were poor correlations between PFA-100
and OPA, and between TXB2 metabolites and platelet
function tests. Levels of TXB2 metabolites and measures of
death after cardiac transplantation. Cardiac event rates were
67% at 20 years and 60% at 25 years, the majority being
percutaneous coronary intervention and reoperation. The
20-year patency rate was 87% for internal thoracic artery
grafts, and 44% for saphenous vein grafts.
Conclusions: The 25-year survival is excellent after coronary
bypass for Kawasaki disease, although there is a significant
need for re-intervention. The internal thoracic artery grafts
performed best.
Perspective: Overall, surgical or percutaneous intervention for
Kawasaki disease is rare and is required only for the most
severe cases. The take-home message from this paper
includes the overall safety and efficacy of coronary bypass in
Kawasaki disease, the important role for the use of the
internal mammary artery, and the necessity for lifetime fol-
low-up because of the likely need for re-intervention.  
Summary written by: Timothy B. Cotts, MD    
General Cardiology
Association of Cytochrome P450 2C19 Genotype
With the Antiplatelet Effect and Clinical Efficacy of
Clopidogrel Therapy 
Shuldiner AR, O’Connell JR, Bliden KP, et al.
JAMA 2009;302:849–857. 
Study Question: What gene variants are associated with
reduced platelet response to clopidogrel therapy and
increased coronary events following percutaneous coronary
intervention (PCI)?
Methods: Clopidogrel was administered for 7 days to 429
healthy Amish persons and followed by ex vivo platelet
aggregometry. A genome-wide association study was per-
formed, followed by genotyping the loss-of-function
cytochrome P450 (CYP) 2C19*2 variant (rs4244285). These
findings were extended by examining the relation of the
CYP2C19*2 genotype to platelet function and cardiovascular
outcomes in an independent sample of 227 patients under-
going PCI. 
Results: Platelet response to clopidogrel was highly heritable
(h2 = 0.73; p < 0.001). Thirteen single-nucleotide polymor-
phisms (SNPs) on chromosome 10q24 within the
CYP2C18–CYP2C19–CYP2C9–CYP2C8 cluster were associ-
ated with diminished clopidogrel response. The rs12777823
polymorphism was in strong linkage disequilibrium with the




platelet function demonstrated marked variability between
the two visits, suggesting that aspirin resistance is not pre-
dictable over time.
Conclusions: The prevalence of aspirin resistance is dependent
on the method of testing, and there is significant variation
in the antiplatelet effect of aspirin, as measured by these
assays.
Perspective: Some literature suggests worse outcome in
patients with aspirin resistance, although the strength varies
based on the assay used. There is no consensus on what
defines platelet resistance to aspirin, and this study shows
little correlation between different assays in defining
aspirin-resistant versus aspirin-sensitive state. Currently, no
good data support routine evaluation for aspirin resistance
in daily clinical practice.  
Summary written by: Hitinder S. Gurm, MD      
Perioperative Safety in the Longitudinal
Assessment of Bariatric Surgery
Flum DR, Belle SH, King WC, et al., on behalf of the Longitudinal
Assessment of Bariatric Surgery (LABS) Consortium.
N Engl J Med 2009;361:445–454.
Study Question: What are the risks and risk factors associated
with bariatric surgical procedures?
Methods: A prospective, multicenter, observational study of
30-day outcomes was conducted in consecutive patients
undergoing bariatric surgical procedures at 10 clinical sites
in the United States from 2005 through 2007. A composite
endpoint of 30-day major adverse outcomes was evaluated.
Results: There were 4,776 patients who had a first-time
bariatric procedure (mean age, 44.5 years; 21.1% men
median body mass index [BMI], 46.5 kg/m2). At least one
coexisting condition was present in 82.1%, 53.9% had two
or more, and 26.5% had three or more. The most common
were hypertension (55.1%), obstructive sleep apnea (48.9%),
diabetes (33.2%), and asthma (23.1%). A Roux-en-Y gastric
bypass was performed in 3,412 patients (87.2% performed
laparoscopically), and laparoscopic adjustable gastric band-
ing was performed in 1,198 patients; 166 patients
underwent other procedures and were not included in the
analysis. The 30-day rate of death among patients who
underwent a Roux-en-Y gastric bypass or laparoscopic
adjustable gastric banding was 0.3%; 4.3% of patients had at
least one major adverse outcome. 
Conclusions: The overall risk of death and adverse outcomes
after bariatric surgery was low and varied considerably
according to patient characteristics. In helping patients make
appropriate choices, short-term safety, long-term effects of
bariatric surgery, and the risks associated with being
extremely obese should be considered.
Perspective: The morbidity and mortality of bariatric surgery is
considerably less than in original reports, and quality of life
continues to improve. The relatively short-term (few years)
results include major weight loss, improved exercise capacity,
improved blood pressure and glycemic control, and improved
quality of life. Guidelines now support having bariatric surgery
in the morbidly obese and in those with diabetes or multiple
risk factors with a BMI >35 kg/m2.  
Summary written by: Melvyn Rubenfire, MD 
Sex Differences in Mortality Following Acute
Coronary Syndromes
Berger JS, Elliott L, Gallup D, et al.
JAMA 2009;302:874–882.
Study Question: Do sex-related differences exist in mortality
after acute coronary syndromes (ACS)?
Methods: A convenience sample of patients from 11 inde-
pendent randomized ACS clinical trials was used for the
analysis. Trials were conducted between 1993 and 2006.
Patients were grouped by ACS type: unstable angina (UA),
ST-elevation myocardial infarction (STEMI), and non-
STEMI (NSTEMI). The primary outcome of interest was
30-day mortality 
Results: A total of 136,247 patients were included; 28% were
women. For those with STEMI, 26% were women, for
NSTEMI 29% were women, and for UA 40% were women.
Overall, 30-day mortality was 9.6% for women and 5.3% for
men. For ACS, among STEMI patients, women were more
likely to experience 30-day mortality. Women with
NSTEMI had lower mortality rates and UA. In a cohort of
patients (n = 35,128) with angiographic data, women were
more likely to have nonobstructive coronary artery disease
(15% vs. 8%), and less likely to have two- (25% vs. 28%) and
three-vessel coronary disease (23% vs. 26%), regardless of
ACS type. After adjustment for angiographic disease sever-
ity, no differences in 30-day mortality were observed
between men and women, regardless of ACS type.
Conclusions: Differences in 30-day mortality rates between
men and women differed between ACS types, largely
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these newer devices with IABP are needed to determine
their impact on survival.  
Summary written by: Ragavendra R. Baliga, MBBS
Interventional Cardiology
Sirolimus-Eluting Stent Treatment at High-Volume
Centers Confers Lower Mortality at 6-Month 
Follow-Up: Results From the Prospective
Multicenter German Cypher Registry
Khattab AA, Hamm CW, Senges J, et al., on behalf of the German
Cypher Registry.
Circulation 2009;120:600–606.
Study Question: Is there a relation between institutional pro-
cedure volume and outcome in patients undergoing
percutaneous coronary intervention (PCI) with the Cypher
stent?
Methods: This was a secondary analysis of the German Cypher
registry. The registry enrolled 8,201 patients treated with
sirolimus-eluting stents (SES) between April 2002 and
September 2005 in 51 centers. The authors categorized hospi-
tals into those that recruited >400 patients as high-volume,
150-400 patients as intermediate-volume, and <150 patients
as low-volume centers.
Results: Patients at low-volume centers were more likely to
present with acute coronary syndrome (ACS) and be
younger and diabetic. Low-volume centers used shorter and
smaller diameter stents, and the deployment pressures were
lower. Major cardiac adverse events occurred in 11.3%,
12.1%, and 9.0% of patients in the low-, intermediate-, and
high-volume center groups, respectively. This gradient in
outcome was observed both in patients with stable coronary
artery disease (2.8%, 1.8%, and 1.2%) and ACS (6.0%,
3.9%, and 2.4%), respectively. Difference in death/myocar-
dial infarction remained significant after adjustment for
baseline factors.
Conclusions: Patients treated with SES stents at low-volume
centers have a worse outcome.
Perspective: This study provides further support for mandating
minimum procedure volume standards for institutions. A
strong argument is often made in the name of patient conven-
ience for expanding elective PCI to sites with no surgical
backup. Although the need for surgical backup is infrequent,
expanding PCI to more centers could replace a few high-
explained by clinical differences at presentation and disease
severity.
Perspective: These findings suggest that differences in short-
term mortality after ACS may be related to coronary artery
disease severity, rather than sex.  
Summary written by: Elizabeth A. Jackson, MD   
Heart Failure/Transplant
Percutaneous Left Ventricular Assist Devices vs.
Intra-Aortic Balloon Pump Counterpulsation for
Treatment of Cardiogenic Shock: A Meta-Analysis
of Controlled Trials
Cheng JM, den Uil CA, Hoeks SE, et al.
Eur Heart J 2009;Jul 18:[Epub ahead of print].
Study Question: What are the potential benefits of percuta-
neous left ventricular assist devices (LVADs) on
hemodynamics and 30-day survival in patients with cardio-
genic shock?
Methods: Two independent investigators searched for all con-
trolled trials using percutaneous LVADs in patients with
cardiogenic shock, where after data were extracted using stan-
dardized forms. Weighted mean differences for cardiac index,
mean arterial pressure, and pulmonary capillary wedge pres-
sure (PCWP) were calculated. Relative risks were calculated
for 30-day mortality, leg ischemia, bleeding, and sepsis.
Results: After device implantation, percutaneous LVAD
patients had higher cardiac index, higher mean arterial pres-
sure, and lower PCWP compared with intra-aortic balloon
pump (IABP) patients. Similar 30-day mortality was observed
using percutaneous LVADs compared with IABPs. Bleeding
was significantly more observed in TandemHeart patients
compared with patients treated with IABP.
Conclusions: Although percutaneous LVADs provide superior
hemodynamic support in patients with cardiogenic shock
compared with IABPs, the use of these more powerful
devices did not improve early survival. Results do not yet
support percutaneous LVADs as a first-choice approach in
the mechanical management of cardiogenic shock.
Perspective: The key take-home message is that the percuta-
neous LVADs are associated with better hemodynamics.
Until recently, most centers have used percutaneous
LVADs for sicker patients. Direct comparisons between




volume centers with multiple low-volume centers, and poten-
tially lead to a decrease in safety and quality of care.  
Summary written by: Hitinder S. Gurm, MD 
The Dissociation Between Door-to-Balloon Time
Improvement and Improvements in Other Acute
Myocardial Infarction Care Processes and 
Patient Outcomes
Wang TY, Fonarow GC, Hernandez AF, et al.
Arch Intern Med 2009;169:1411–1419.
Study Question: What is the correlation between improvement
in specific targeted quality measures (such as door-to-balloon
[DTB] time) and other quality measures and outcomes?
Methods: The authors studied the association between
improvement in D2B time at 101 hospitals participating in
the Get With the Guidelines program from 2005 to 2007
with changes in composite Centers for Medicare and
Medicaid Services/Joint Commission on Accreditation of
Healthcare Organizations (CMS/JCAHO) core measure
performance and in-hospital mortality.
Results: The mean D2B time decreased from 101 to 87 min-
utes, whereas hospital composite CMS/JCAHO core measure
performance increased from 93.4% to 96.4%. Mortality rates
declined from 5.1% to 4.7%. There was no correlation
between improvement in hospital D2B time and changes in
composite quality performance or in-hospital mortality. Lack
of association between these measures persisted after adjust-
ment for differences in patient mix.
Conclusions: Within the Get With the Guidelines program,
there was no correlation between DTB time improvement and
changes in other quality measures or mortality.
Perspective: Hospitals participating in the Get With the
Guidelines program achieved remarkable improvement in the
CMS/JCAHO core measures, with scores in the high 90s
before the start of this study. It is plausible that a ceiling
effect limited the magnitude of improvement in core measures
while there was significant room for improvement in D2B
time. This may have limited the ability to detect a possible
association between improvements in the measures. More
likely, the results of the study reflect the need for broader
quality improvement efforts to achieve improvement in all
aspects of health care delivery.  
Summary written by: Hitinder S. Gurm, MD
Noninvasive Cardiology
Dramatic Reduction in Infective Endocarditis-
Related Mortality With a Management-Based
Approach
Botelho-Nevers E, Thuny F, Casalta JP, et al.
Arch Intern Med 2009;169:1290–1298.
Study Question: Does a standardized diagnostic and therapeutic
protocol impact outcome among patients with infective endo-
carditis (IE), and does outcome correlate with compliance with
the management-based protocol?
Methods: At a single tertiary care teaching hospital in France,
an observational study was performed between 1991 and 2006
that included 333 consecutive patients treated for IE. The
study was divided into two time periods: 1991 to 2001, before
implementation of a standardized therapeutic protocol (173
patients); and 2002 to 2006, after implementation of the pro-
tocol (160 patients). The management protocol evaluated a
sampling of biological specimens; and used only four antimi-
crobial agents with standardized duration of treatment,
standardized surgical indications, and 1 year of close follow-up.
Results: The 1-year mortality decreased significantly from
18.5% during the initial period to 8.2% after initiation of the
standardized protocol. After multivariable analysis, manage-
ment with the standardized protocol remained a strong
protective factor. During the latter period, there was signifi-
cantly better compliance in antimicrobial therapy and fewer
cases of renal failure. Deaths by embolic events and multiple
organ failure also significantly decreased during the latter
period.
Conclusions: A dramatic reduction in mortality was observed
during the implementation of a standardized protocol for the
management of IE, suggesting that a management-based
approach has a significant impact on IE outcome.
Perspective: The study is of interest, and shows better compli-
ance with appropriate antibiotic regimens, and improved
outcomes after the implementation of a standardized proto-
col for management. This study supports consideration for
more standardized approaches for IE management. In addi-
tion, there might be fertile ground for more standardized
approaches to diagnosis of IE—despite the general accept-
ance of the modified Duke criteria, do we really need all
those transesophageal echocardiograms to ‘rule out’ IE?  
Summary written by: David S. Bach, MD
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Subclinical Brain Embolization in Left-Sided
Infective Endocarditis. Results From the Evaluation
by MRI of the Brains of Patients With Left-Sided
Intracardiac Solid Masses (EMBOLISM) Pilot Study
Cooper HA, Thompson EC, Laureno R, et al.
Circulation 2009;120:585–591.
Study Question: What is the actual incidence of acute brain
embolization in patients with left-sided infective endocarditis
(IE)?
Methods: A cohort of 56 patients with definite left-sided IE
was prospectively studied. Patients were examined by a neu-
rologist, and those without contraindication had magnetic
resonance imaging (MRI) of the brain. Patients without
clinical evidence of acute stroke, but with MRI evidence of
acute brain embolization, were considered to have subclinical
brain embolization. 
Results: Clinical stroke was present in 25% of patients.
Among 40 patients undergoing MRI, incidence rates of sub-
clinical and any acute brain embolization were 48% and
80%, respectively. Acute brain embolization was present in
95% of patients with Staphylococcus aureus infection. At 3
months, mortality was similar among patients with clinical
stroke and subclinical brain embolization, and was higher
among patients with any acute brain embolization than
those without. Valvular surgery was performed in 25 patients
(45%), including 16 with acute brain embolization, at a
median of 4 days. Surgery was independently associated with
a lower risk of mortality at 3 months. 
Conclusions: MRI detected subclinical brain embolization in a
substantial number of patients with left-sided IE, suggesting
that the incidence of acute brain embolization may be signif-
icantly higher than reports based on clinical and computed
tomography (CT) findings have indicated. Brain MRI may
play a role in the complex decision about surgical interven-
tion in IE.
Perspective: This is a provocative study, suggesting that sub-
clinical brain embolization commonly complicates left-sided
IE. Among 40 patients without clinical evidence of stroke,
MRI revealed evidence of acute brain embolization in 80%.
Additional study may be required to sort out whether MRI
evidence of acute brain embolization is an indication, or a
contraindication, to early surgery in patients with active left-
sided IE.  
Summary written by: David S. Bach, MD 
Prevention/Vascular
Apixaban or Enoxaparin for Thromboprophylaxis
After Knee Replacement
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ.
N Engl J Med 2009;361:594-604.
Study Question: What is the safety and efficacy of a factor Xa
inhibitor, apixaban, versus a low molecular weight heparin,
enoxaparin, for thromboprophylaxis after major joint replace-
ment surgery?
Methods: Subjects undergoing total knee replacement were
randomized to 2.5 mg of apixaban orally daily, or 30 mg of
subcutaneous enoxaparin twice daily, both started 12-24
hours after surgery and continued for 10-14 days. All subjects
underwent bilateral venography, and the primary efficacy out-
come was a composite of asymptomatic and symptomatic
deep vein thrombosis, nonfatal pulmonary embolism, and
death from any cause. Follow-up was for 60 days. 
Results: Of 3,195 patients who underwent randomization, 908
subjects were not eligible for efficacy analysis, although all but
11 subjects were included in the safety analysis. The overall
rate of primary outcome events was much lower than
expected, with the rate of primary efficacy outcome of 9.0%
and 8.8% in the apixaban and enoxaparin groups, respectively.
The composite incidence of major bleeding or clinically rele-
vant nonmajor bleeding was 2.9% versus 4.3% with apixaban
and enoxaparin, respectively.
Conclusions: For efficacy of thromboprophylaxis after knee
replacement surgery, a comparison of enoxaparin and apixa-
ban did not meet prespecified statistical criteria for
noninferiority. Use of apixaban was associated with lower
rates of clinically relevant bleeding, and it had a similar
adverse event profile.
Perspective: Despite planning to use venography in all subjects,
this study suffered from a lower than expected number of out-
comes, rendering it underpowered to answer the study
question. Although this study provides some hope that factor
Xa inhibitors may prove as efficacious and yet safer than low
molecular weight heparin, there remains significant contro-
versy as to the necessity of such aggressive thrombo-
prophylaxis, even after high-risk surgery. Finding the ideal
agent remains an elusive goal. The current study contributes
to the hope that newer agents may bring us closer to that
goal.  
Summary written by: James B. Froehlich, MD




Association of Cardiovascular Risk Factors With
Mental Health Diagnoses in Iraq and Afghanistan
War Veterans Using VA Health Care
Cohen BE, Marmar C, Ren L, Bertenthal D, Seal KH.
JAMA 2009;302:489-492.
Study Question: Are cardiovascular risk factors common
among Iraq and Afghanistan war veterans with mental
health disorders?
Methods: Data from the Veterans Administration (VA) roster
were used to identify veterans who had access to VA health
care from October 7, 2001 to September 30, 2008. Veterans
were grouped by the presence of mental health diagnosis (no
mental health diagnosis, mental health diagnosis with no
post-traumatic stress disorder [PTSD]; and mental health
diagnosis with PTSD). Sex-stratified, multivariate logistic
regression was used to examine association of these groups
with cardiovascular risk factors. 
Results: A total of 303,223 veterans were included (mean age
31 years; 88% men). PTSD was common among the cohort
(24%); among those, comorbid mental health conditions
were prevalent including depression (53%), anxiety disorder
(29%), adjustment disorder (26%), and alcohol use disorder
(22%). Veterans with mental health diagnosis were more
likely to have cardiovascular risk factors including tobacco
use, hypertension, hyperlipidemia, and obesity compared to
those without mental health disorders, after controlling for
multiple factors.
Conclusions: Cardiovascular risk factors are common among
veterans with mental health disorders.
Perspective: These findings suggest the critical need for risk
factor modification and prevention among a young population
of veterans. Whether risk factor modification with or without
treatment of mental health disorders in this population will
reduce cardiovascular events will need to be assessed in future
prospective trials.  
Summary written by: Elizabeth A. Jackson, MD 
Effect of Telmisartan on Renal Outcomes: A
Randomized Trial
Mann JF, Schmieder RE, Dyal L, et al., on behalf of the TRANSCEND
(Telmisartan Randomised Assessment Study in ACE Intolerant
Subjects With Cardiovascular Disease) Investigators.
Ann Intern Med 2009;151:1-10.
Study Question: What are the long-term renal effects of telmis-
artan versus placebo in adults with cardiovascular disease?
Methods: The authors reported results of the TRANSCEND
study, a randomized trial of telmisartan 80 mg/d versus
placebo in subjects greater than age 55 with known coronary
artery disease or diabetes mellitus and end-organ damage
(but no microalbuminuria), who were intolerant of
angiotensin-converting enzyme inhibitors. Prespecified renal
outcome of dialysis, doubling of serum creatinine, death, as
well as changes in glomerular filtration rate (GFR) and albu-
minuria were reported. 
Results: Among 5,927 adults randomized to telmisartan (n =
2,954) or matching placebo (n = 2,972), there was no sig-
nificant difference in the composite renal outcome (58
patients [1.96%] vs. 46 patients [1.55%] in the ARB and
placebo groups, respectively). Serum creatinine doubled in
56 and 36 telmisartan and placebo patients, respectively.
Fewer telmisartan than placebo patients had an increase in
albuminuria (32% vs. 63%). GFR decreased significantly
more in the telmisartan group than placebo (mean change
in estimated GFR, -3.2 ml/min per 1.73 m2 vs. -0.26
ml/min per 1.73 m2).
Conclusions: In adults with vascular disease but without
microalbuminuria, the effects of telmisartan on major renal
outcomes were similar to those of placebo.
Perspective: This study suggests that angiotensin-receptor
blocker (ARB) therapy in patients with vascular disease, but
without evidence of nephropathy, does not prevent progres-
sion to renal dysfunction. Since the renal outcomes are of
unclear clinical significance, but ARB use was associated
with an improvement in cardiovascular outcomes, consider-
ation for cardiovascular events should dominate decisions
regarding use of these agents. This study provides no data
supporting an expectation of ARB-associated improvement
in renal outcomes in patients with vascular disease, but no
nephropathy.  
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